Geneva Partners’s Novo Nordisk NVO Stock Holding History

Geneva Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,405	Closed	-$981K	–	72
2024 Q4	$981K	Sell	11,405 -43,602	-79%	-$4.72M	0.4%	45
2024 Q3	$6.55M	Sell	55,007 -5,705	-9%	-$761K	2.84%	12
2024 Q2	$8.67M	Sell	60,712 -935	-2%	-$124K	3.57%	7
2024 Q1	$7.92M	Sell	61,647 -210	-0.3%	-$25K	3.49%	7
2023 Q4	$6.4M	Buy	61,857 +9,851	+19%	+$974K	3.54%	9
2023 Q3	$4.73M	Buy	52,006 +1,860	+4%	+$164K	3.14%	13
2023 Q2	$3.91M	Buy	50,146 +9,144	+22%	+$747K	2.55%	16
2023 Q1	$3.26M	Sell	41,002 -700	-2%	-$49.6K	2.79%	15
2022 Q4	$2.82M	Buy	41,702 +20,090	+93%	+$1.18M	2.67%	14
2022 Q3	$1.08M	Buy	+21,612	New	+$1.16M	1.23%	26

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Geneva Partners's NVO Position: Q1 2025 in Review

Geneva Partners sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 11,405 shares — an estimated $981K sold.

Geneva Partners first reported a position in NVO in Q3 2022 and held it in 10 quarters. The position peaked at $8.67M in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

Geneva Partners reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
Geneva Partners sold 11,405 Novo Nordisk shares in Q1 2025, an estimated $981K.
Geneva Partners first reported a position in Novo Nordisk in Q3 2022 and held it in 10 quarters.
Geneva Partners's Novo Nordisk position peaked at $8.67M in Q2 2024.
1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Geneva Partners's 13F filing for Q1 2025, filed 30 Apr 2025.